IL2 and cervical carcinoma: Notably, treatment with CM derived from breast and cervical cancer cell lines, that is, KPL4 and Hela cells, led to a significant reduction in IL‐2 mRNA expression in activated Jurkat T cells compared with that in the untreated control (Figure 1A).